EyePoint Pharmaceuticals (STU:PV3B) Ending Cash Position : €78.91 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Ending Cash Position?

EyePoint Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2025 was €78.91 Mil.

EyePoint Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2024 (€72.06 Mil) to Dec. 2024 (€95.36 Mil) but then declined from Dec. 2024 (€95.36 Mil) to Mar. 2025 (€78.91 Mil).

EyePoint Pharmaceuticals's annual Ending Cash Position increased from Dec. 2022 (€90.42 Mil) to Dec. 2023 (€258.06 Mil) but then declined from Dec. 2023 (€258.06 Mil) to Dec. 2024 (€95.36 Mil).

EyePoint Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for EyePoint Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Ending Cash Position Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

37.04

158.19

90.42

258.06

95.36

EyePoint Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															249.47	84.46	72.06	95.36	78.91

EyePoint Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

EyePoint Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	268.75	+	-173.389
	=	95.36

EyePoint Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	92.365	+	-13.455
	=	78.91

EyePoint Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals Headlines

No Headlines